News from trovagene, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 04, 2014, 09:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Announces Presentation of Clinical Data at the 56th American Society of Hematology Annual Meeting

 Trovagene, Inc. (NASDAQ:  TROV), today announced that clinical data will be presented at the 56th American Society of Hematology (ASH)...

Nov 26, 2014, 09:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene to Present at 26th Annual Piper Jaffray Healthcare Conference

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D....

Nov 20, 2014, 09:08 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced today clinical study results highlighting the...

Nov 12, 2014, 08:15 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene to Present at Upcoming Healthcare Conferences

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh,...

Nov 06, 2014, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Announces Third Quarter 2014 Financial Results

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine...

Oct 29, 2014, 08:10 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease

Trovagene Schedules Release of Third Quarter 2014 Financial Results and Investor Conference Call

Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the...

Oct 27, 2014, 08:10 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery

 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, today announced the publication of clinical study results...

Oct 06, 2014, 16:30 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene to Present at 13th Annual BIO Investor Forum

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius...

Oct 01, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium

Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending...

Sep 29, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Expands Clinical Program with New Study Evaluating its Precision Cancer Monitoring Platform in Lung Cancer

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical...

Sep 17, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined...

Aug 26, 2014, 08:24 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics

Trovagene, Inc. (NASDAQ:  TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation...

Aug 25, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent...

Aug 20, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Provides Update on Its Urine-Based HPV Test

Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will...

Aug 12, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined...

Aug 07, 2014, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene, Inc. Announces Second Quarter 2014 Financial Results

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months...

Jul 30, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call

Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the...

Jul 01, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance

 Trovagene, Inc. (NASDAQ:  TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from...

Jun 30, 2014, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute

 Trovagene, Inc. (NASDAQ:  TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the...

Jun 16, 2014, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.  (PRNewsFoto/Trovagene, Inc.)

Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. (NASDAQ:  TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to...